VSee Health, Inc. announced on June 23, 2025, its selection to support an NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation, based out of UCLA. This marks the second national trial of post-stroke telerehabilitation that VSee has been involved in.
The trial spans 29 hospitals and 202 patients, evaluating the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors. This aims to reduce costs such as transportation, caregiver burdens, and hospital readmissions.
Co-CEO Dr. Milton Chen stated that this Phase 3 trial validates telehealth as a scalable, cost-effective model for neurorehabilitation, positioning VSee as a go-to platform for value-based virtual care. The proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328 million global stroke rehab market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.